Toolkit/H-2Kb-ADSCs

H-2Kb-ADSCs

Construct Pattern·Research·Since 2026

Also known as: adipose-derived MSCs expressing an allogeneic class I MHC protein, H-2K^b-ADSCs

Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

lentiviral transduction was used to generate adipose-derived MSCs (ADSCs) from DBA/2J (H-2d) mice which expressed an allogeneic class I MHC protein (H-2Kb).

Usefulness & Problems

Why this is useful

This engineered ADSC product expresses the allogeneic class I MHC protein H-2Kb on otherwise autologous DBA/2J adipose-derived MSCs. The paper uses it to test how MSC-delivered allo-antigen changes therapeutic and immune outcomes in diabetic nephropathy.; testing how MSC-delivered allo-antigen expression alters therapeutic effects in diabetic nephropathy; probing the balance between immunomodulatory benefit and alloimmune risk after repeated intravenous MSC dosing

Source:

This engineered ADSC product expresses the allogeneic class I MHC protein H-2Kb on otherwise autologous DBA/2J adipose-derived MSCs. The paper uses it to test how MSC-delivered allo-antigen changes therapeutic and immune outcomes in diabetic nephropathy.

Source:

testing how MSC-delivered allo-antigen expression alters therapeutic effects in diabetic nephropathy

Source:

probing the balance between immunomodulatory benefit and alloimmune risk after repeated intravenous MSC dosing

Problem solved

It enables a controlled comparison between autologous ADSCs and autologous ADSCs carrying a defined allogeneic MHC signal. This helps isolate the contribution of allo-antigen display to efficacy and immunogenicity.; provides an engineered autologous ADSC product that presents a defined allogeneic MHC-I allo-antigen for mechanistic comparison against autologous control ADSCs

Source:

It enables a controlled comparison between autologous ADSCs and autologous ADSCs carrying a defined allogeneic MHC signal. This helps isolate the contribution of allo-antigen display to efficacy and immunogenicity.

Source:

provides an engineered autologous ADSC product that presents a defined allogeneic MHC-I allo-antigen for mechanistic comparison against autologous control ADSCs

Problem links

provides an engineered autologous ADSC product that presents a defined allogeneic MHC-I allo-antigen for mechanistic comparison against autologous control ADSCs

Literature

It enables a controlled comparison between autologous ADSCs and autologous ADSCs carrying a defined allogeneic MHC signal. This helps isolate the contribution of allo-antigen display to efficacy and immunogenicity.

Source:

It enables a controlled comparison between autologous ADSCs and autologous ADSCs carrying a defined allogeneic MHC signal. This helps isolate the contribution of allo-antigen display to efficacy and immunogenicity.

Published Workflows

Effects of Repeated Intravenous Injections of Autologous Adipose-Derived Mesenchymal Stromal Cells Expressing an Allogeneic MHC Protein in a Mouse Model of Diabetic Nephropathy.

2026

Objective: Engineer autologous adipose-derived mesenchymal stromal cells to express an allogeneic MHC-I protein and compare their therapeutic and immunological effects against autologous control ADSCs in a mouse model of diabetic nephropathy.

Why it works: The study rationale is that introducing a defined allogeneic MHC mismatch into otherwise autologous ADSCs can reveal how MSC-delivered allo-antigens alter anti-inflammatory and renal repair effects while also exposing adverse immune responses.

MSC-delivered allo-antigen presentationregulatory T cell enhancementreduced intra-renal myeloid infiltrationlentiviral transductionintravenous cell administrationcomparative in vivo efficacy assessment

Stages

  1. 1.
    Engineering of allo-MHC-expressing autologous ADSCs(library_build)

    This stage creates the engineered cell product needed to test how MSC-delivered allo-antigen affects therapeutic and immune outcomes.

    Selection: Generate DBA/2J ADSCs expressing the allogeneic class I MHC protein H-2Kb using lentiviral transduction.

  2. 2.
    Repeated intravenous treatment in diabetic mice(confirmatory_validation)

    This stage tests whether the engineered allo-MHC feature changes therapeutic performance in an established disease setting.

    Selection: Compare H-2Kb-ADSCs, EV-ADSCs, and vehicle after dosing at 11 and 13 weeks after diabetes initiation.

  3. 3.
    Immune and safety characterization(secondary_characterization)

    This stage determines whether improved renal outcomes are accompanied by beneficial immune regulation, harmful alloimmunity, or both.

    Selection: Assess immune modulation and adverse immunological consequences associated with H-2Kb-ADSC treatment.

Steps

  1. 1.
    Lentiviral transduction of DBA/2J ADSCs to express H-2Kbengineered cell product

    Create autologous ADSCs carrying a defined allogeneic MHC-I protein.

    The engineered cell product must exist before in vivo comparison of therapeutic and immune effects can be performed.

  2. 2.
    Repeated intravenous administration of engineered or control ADSCstherapeutic cell products

    Test therapeutic effects of H-2Kb-ADSCs against EV-ADSC and vehicle controls in established diabetic nephropathy.

    In vivo dosing follows cell engineering so the resulting products can be compared under the same disease timeline.

  3. 3.
    Week-15 comparison of renal functional and structural indicestested therapeutic cell products

    Measure whether engineered allo-MHC expression changes renal outcomes relative to autologous control ADSCs and vehicle.

    Outcome assessment is performed after repeated dosing to capture treatment effects in the established disease model.

  4. 4.
    Assess immune modulation and adverse immunological outcomesengineered therapeutic cell product under immune/safety evaluation

    Determine whether superior renal benefit is associated with Treg-linked immune modulation and whether alloimmune or organ-injury liabilities emerge.

    Immune and safety analysis follows efficacy readout to interpret mechanism and detect tradeoffs introduced by allo-MHC expression.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Architecture: A reusable architecture pattern for arranging parts into an engineered system.

Techniques

No technique tags yet.

Target processes

recombination

Input: Chemical

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: sensor

The abstract supports a need for DBA/2J-derived ADSCs, lentiviral transduction, and intravenous dosing into diabetic DBA/2J mice. It also implies renal, immune, and liver injury readouts are needed to evaluate outcomes.; requires lentiviral transduction of DBA/2J adipose-derived MSCs; requires repeated intravenous administration in the mouse model used here; depends on expression of the allogeneic MHC-I protein H-2Kb

It does not avoid adverse immune consequences, because the abstract reports alloantibodies and inflammatory liver injury. It also did not improve glycemia or survival in this study.; elicited increased circulating anti-H-2Kb IgG antibodies; was associated with histological and biochemical evidence of inflammatory liver injury; did not influence glycemia or survival in the reported comparison

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Observations

mixedMouseapplication demomousemale DBA/2J mice with established diabetes

renal functional and structural comparison

Inferred from claim c2 during normalization. H-2Kb-ADSCs had superior beneficial effects on diabetic nephropathy severity compared with fully autologous EV-ADSCs. Derived from claim c2. Quoted text: However, H-2Kb-ADSCs recipients had greater reductions in BUN and uACR ... These novel findings demonstrated that ADSCs expressing an MHC-I allo-antigen had superior beneficial effects on DN than fully autologous ADSCs.

Source:

blood urea nitrogen(greater_reduction_than)urine albumin creatinine ratio(greater_reduction_than)
successMouseapplication demomousemale DBA/2J mice with established diabetes

immune profiling

Inferred from claim c3 during normalization. Improved diabetic nephropathy severity with H-2Kb-ADSCs was associated with immune modulation including Treg enhancement and reduced intra-renal myeloid cell infiltration. Derived from claim c3. Quoted text: H-2Kb-ADSCs recipients had ... reduced intra-renal myeloid cell infiltration, increased splenic regulatory T cell (Treg) proportions and increased intra-renal Treg infiltration and FOXP3 and IL-10 mRNA.

Source:

FOXP3 mRNA(increased)IL-10 mRNA(increased)intra-renal myeloid cell infiltration(reduced)intra-renal Treg infiltration(increased)splenic regulatory T cell proportions(increased)
mixedMouseapplication demomousemale DBA/2J mice with established diabetes

immune and tissue injury assessment

Inferred from claim c4 during normalization. H-2Kb-ADSC treatment also produced potentially detrimental immunological effects including alloantibodies and inflammatory liver injury. Derived from claim c4. Quoted text: Nonetheless, recipients of H-2Kb-ADSCs also had decreased splenic CD4/CD8 T cell ratios, increased circulating anti-H-2Kb IgG antibodies and histological and biochemical evidence of inflammatory liver injury.

Source:

circulating anti-H-2Kb IgG antibodies(increased)inflammatory liver injury(present)splenic CD4/CD8 T cell ratio(decreased)
mixedMouseapplication demomousemale DBA/2J mice with diabetes

physiological outcome assessment

Inferred from claim c5 during normalization. Neither EV-ADSCs nor H-2Kb-ADSCs influenced glycemia or survival in the reported study. Derived from claim c5. Quoted text: Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced ... compared to vehicle alone, without influencing glycemia or survival.

Source:

glycemia(no_change)survival(no_change)
successMousetherapeutic usemousemale DBA/2J mice with diabetes

renal functional and structural indices

Inferred from claim c1 during normalization. Both EV-ADSCs and H-2Kb-ADSCs reduced renal injury indices compared with vehicle alone in diabetic DBA/2J mice. Derived from claim c1. Quoted text: Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced kidney/total body weight ratio, blood urea nitrogen (BUN), urine albumin creatinine ratio (uACR), mesangial matrix expansion (MME) and renal fibrosis compared to vehicle alone

Source:

blood urea nitrogen(reduced_vs)kidney/total body weight ratio(reduced_vs)mesangial matrix expansion(reduced_vs)renal fibrosis(reduced_vs)urine albumin creatinine ratio(reduced_vs)

Supporting Sources

Ranked Claims

Claim 1adverse immunological effectsupports2026Source 1needs review

H-2Kb-ADSC treatment also produced potentially detrimental immunological effects including alloantibodies and inflammatory liver injury.

Nonetheless, recipients of H-2Kb-ADSCs also had decreased splenic CD4/CD8 T cell ratios, increased circulating anti-H-2Kb IgG antibodies and histological and biochemical evidence of inflammatory liver injury.
circulating anti-H-2Kb IgG antibodies in H-2Kb-ADSC recipientsinflammatory liver injury histological and biochemical evidencesplenic CD4/CD8 T cell ratio in H-2Kb-ADSC recipients
Claim 2comparative superioritysupports2026Source 1needs review

H-2Kb-ADSCs had superior beneficial effects on diabetic nephropathy severity compared with fully autologous EV-ADSCs.

However, H-2Kb-ADSCs recipients had greater reductions in BUN and uACR ... These novel findings demonstrated that ADSCs expressing an MHC-I allo-antigen had superior beneficial effects on DN than fully autologous ADSCs.
blood urea nitrogen H-2Kb-ADSCs vs EV-ADSCsurine albumin creatinine ratio H-2Kb-ADSCs vs EV-ADSCs
Claim 3comparative therapeutic effectsupports2026Source 1needs review

Both EV-ADSCs and H-2Kb-ADSCs reduced renal injury indices compared with vehicle alone in diabetic DBA/2J mice.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced kidney/total body weight ratio, blood urea nitrogen (BUN), urine albumin creatinine ratio (uACR), mesangial matrix expansion (MME) and renal fibrosis compared to vehicle alone
blood urea nitrogen reduced compared to vehicle alonekidney/total body weight ratio reduced compared to vehicle alonemesangial matrix expansion reduced compared to vehicle alonerenal fibrosis reduced compared to vehicle aloneurine albumin creatinine ratio reduced compared to vehicle alone
Claim 4immune modulation associationsupports2026Source 1needs review

Improved diabetic nephropathy severity with H-2Kb-ADSCs was associated with immune modulation including Treg enhancement and reduced intra-renal myeloid cell infiltration.

H-2Kb-ADSCs recipients had ... reduced intra-renal myeloid cell infiltration, increased splenic regulatory T cell (Treg) proportions and increased intra-renal Treg infiltration and FOXP3 and IL-10 mRNA.
FOXP3 mRNA in H-2Kb-ADSC recipientsIL-10 mRNA in H-2Kb-ADSC recipientsintra-renal myeloid cell infiltration in H-2Kb-ADSC recipientsintra-renal Treg infiltration in H-2Kb-ADSC recipientssplenic regulatory T cell proportions in H-2Kb-ADSC recipients
Claim 5no effectsupports2026Source 1needs review

Neither EV-ADSCs nor H-2Kb-ADSCs influenced glycemia or survival in the reported study.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced ... compared to vehicle alone, without influencing glycemia or survival.
glycemia without influencing glycemiasurvival without influencing survival

Approval Evidence

1 source5 linked approval claimsfirst-pass slug h-2kb-adscs
lentiviral transduction was used to generate adipose-derived MSCs (ADSCs) from DBA/2J (H-2d) mice which expressed an allogeneic class I MHC protein (H-2Kb).

Source:

adverse immunological effectsupports

H-2Kb-ADSC treatment also produced potentially detrimental immunological effects including alloantibodies and inflammatory liver injury.

Nonetheless, recipients of H-2Kb-ADSCs also had decreased splenic CD4/CD8 T cell ratios, increased circulating anti-H-2Kb IgG antibodies and histological and biochemical evidence of inflammatory liver injury.

Source:

comparative superioritysupports

H-2Kb-ADSCs had superior beneficial effects on diabetic nephropathy severity compared with fully autologous EV-ADSCs.

However, H-2Kb-ADSCs recipients had greater reductions in BUN and uACR ... These novel findings demonstrated that ADSCs expressing an MHC-I allo-antigen had superior beneficial effects on DN than fully autologous ADSCs.

Source:

comparative therapeutic effectsupports

Both EV-ADSCs and H-2Kb-ADSCs reduced renal injury indices compared with vehicle alone in diabetic DBA/2J mice.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced kidney/total body weight ratio, blood urea nitrogen (BUN), urine albumin creatinine ratio (uACR), mesangial matrix expansion (MME) and renal fibrosis compared to vehicle alone

Source:

immune modulation associationsupports

Improved diabetic nephropathy severity with H-2Kb-ADSCs was associated with immune modulation including Treg enhancement and reduced intra-renal myeloid cell infiltration.

H-2Kb-ADSCs recipients had ... reduced intra-renal myeloid cell infiltration, increased splenic regulatory T cell (Treg) proportions and increased intra-renal Treg infiltration and FOXP3 and IL-10 mRNA.

Source:

no effectsupports

Neither EV-ADSCs nor H-2Kb-ADSCs influenced glycemia or survival in the reported study.

Both EV-ADSCs and H-2Kb-ADSCs resulted in reduced ... compared to vehicle alone, without influencing glycemia or survival.

Source:

Comparisons

Source-stated alternatives

The abstract directly contrasts this construct with empty vector-transduced autologous ADSCs and vehicle alone. It also frames the broader alternative as fully autologous versus allogeneic MSC therapy.

Source:

The abstract directly contrasts this construct with empty vector-transduced autologous ADSCs and vehicle alone. It also frames the broader alternative as fully autologous versus allogeneic MSC therapy.

Source-backed strengths

showed greater reductions in BUN and uACR than empty-vector autologous ADSCs in diabetic DBA/2J mice; was associated with increased splenic and intra-renal Treg-related signals

Source:

showed greater reductions in BUN and uACR than empty-vector autologous ADSCs in diabetic DBA/2J mice

Source:

was associated with increased splenic and intra-renal Treg-related signals

Compared with inkube

H-2Kb-ADSCs and inkube address a similar problem space because they share recombination.

Shared frame: same top-level item type; shared target processes: recombination; same primary input modality: chemical

Compared with stress granule inhibitory peptides

H-2Kb-ADSCs and stress granule inhibitory peptides address a similar problem space because they share recombination.

Shared frame: same top-level item type; shared target processes: recombination; same primary input modality: chemical

Compared with synthetic multienzyme complexes

H-2Kb-ADSCs and synthetic multienzyme complexes address a similar problem space because they share recombination.

Shared frame: same top-level item type; shared target processes: recombination; same primary input modality: chemical

Ranked Citations

  1. 1.
    StructuralSource 1MED2026Claim 1Claim 2Claim 3

    Extracted from this source document.